MentionFox
Home › Executive changes › Allogene Therapeutics, Inc.
Leadership changes · SEC Form 8-K, Item 5.02

Allogene Therapeutics, Inc. executive changes

Every leadership change Allogene Therapeutics, Inc. reported to the SEC under Item 5.02: who left, who was appointed, to what role and from when, quoted from each filing.

Filings2
Latest filing2026-09-02

Allogene Therapeutics, Inc. filed 2 current reports with the SEC under Item 5.02, which covers directors and officers leaving or being appointed, the latest on 2026-09-02. Each change below is quoted from the filing and linked to it.

Every change, newest first

Filed 2026-09-02 · 8-K

Reported

(b) On August 31, 2026, Geoffrey Parker, the Executive Vice President and Chief Financial Officer and principal financial officer of Allogene Therapeutics, Inc. (the "Company"), provided notice of his retirement from the Company in all capacities, effective November 6, 2026.
Filed 2026-05-28 · 8-K

Reported

On May 28, 2026, the Board of Directors (the "Board") of Allogene Therapeutics, Inc. (the "Company"), upon the recommendation of its Nominating and Corporate Governance Committee, approved the appointment of Zachary Roberts, M.D., Ph.D. as the Company's President and Chief Executive Officer, replacing David Chang, M.D., Ph.D. in such capacities.
Hiring for a seat like this?

Find people with the same kind of experience as the senior executive at Allogene Therapeutics, Inc., with the record behind each one.

Find candidates like senior executive at Allogene Therapeutics, Inc.
Selling to Allogene Therapeutics, Inc.?

New leaders review vendors and budgets in their first months. Get an alert the next time Allogene Therapeutics, Inc. is in the news or changes leadership.

Get an alert when Allogene Therapeutics, Inc. changes leadership

Tools for this story

Each opens in a new tab, filled in for Allogene Therapeutics, Inc.. With no account yet, you sign up free and land on the result.

Where this comes from

A public company must file a current report on Form 8-K with the SEC within four business days when a director leaves or is elected, or when its chief executive, chief financial, chief accounting or chief operating officer, or another named executive, departs or is appointed. That disclosure goes under Item 5.02 of the report.

Every change on this page is taken from one of those filings and quoted in the company's own words, with a link to the filing, so it can be checked at the source. Where a filing names the person, the role and the date a change takes effect, they are shown beside the quote. Where it does not, the quote stands on its own. A filing states what changed; it rarely states why, and neither does this page.

Cite this page

Permanent URL: https://mentionfox.com/executive-changes/allogene-therapeutics
Last updated 2026-09-27
Primary record: SEC filing 1 · SEC filing 2
Allogene Therapeutics, Inc. (ALLO) executive changes: 2 leadership filings. MentionFox, 2026-09-27. https://mentionfox.com/executive-changes/allogene-therapeutics